- Home
- CMMB vs SCNX Comparison
CMMB vs SCNX Comparison
Compare CMMB & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | SCNX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 16.2M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CMMB | SCNX |
|---|---|---|
| Price | $2.58 | $0.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $25.00 | $1.50 |
| AVG Volume (30 Days) | 104.2K | ★ 771.9K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | $67.25 | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $1.35 | $0.24 |
| 52 Week High | $3.55 | $2.60 |
Technical Indicators
Market Signals| Indicator | CMMB | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 40.47 |
| Support Level | $1.49 | $0.30 |
| Resistance Level | $2.86 | $0.43 |
| Average True Range (ATR) | 0.22 | 0.03 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 62.13 | 17.56 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.